Castle Biosciences Inc (CSTL) - Total Liabilities
Based on the latest financial reports, Castle Biosciences Inc (CSTL) has total liabilities worth $91.15 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore CSTL long-term investment intensity to see how much of total assets are deployed in long-term investments.
Castle Biosciences Inc - Total Liabilities Trend (2017–2025)
This chart illustrates how Castle Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of Castle Biosciences Inc.
Castle Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Castle Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Gujarat Narmada Valley Fertilizers and Chemicals Limited
NSE:GNFC
|
India | Rs-91.15 Billion |
|
Hangzhou Raycloud Technology Co Ltd
SHG:688365
|
China | CN¥831.09 Million |
|
China Railway Tielong Container Logistics Co Ltd
SHG:600125
|
China | CN¥2.57 Billion |
|
Pricol Limited
NSE:PRICOLLTD
|
India | Rs11.45 Billion |
|
Allied Properties Real Estate Investment Trust
TO:AP-UN
|
Canada | CA$4.63 Billion |
|
Shanxi Sanwei Group Co Ltd
SHE:000755
|
China | CN¥6.66 Billion |
|
Samsung Electro Mechanics Pref
KO:009155
|
Korea | ₩4.80 Trillion |
|
Sumavision Technologies
SHE:300079
|
China | CN¥431.64 Million |
Liability Composition Analysis (2017–2025)
This chart breaks down Castle Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Castle Biosciences Inc balance sheet independence to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.04 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Castle Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Castle Biosciences Inc (2017–2025)
The table below shows the annual total liabilities of Castle Biosciences Inc from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $107.68 Million | +42.82% |
| 2024-12-31 | $75.40 Million | +21.47% |
| 2023-12-31 | $62.07 Million | +28.83% |
| 2022-12-31 | $48.18 Million | -5.22% |
| 2021-12-31 | $50.83 Million | +115.05% |
| 2020-12-31 | $23.64 Million | -31.75% |
| 2019-12-31 | $34.63 Million | +6.65% |
| 2018-12-31 | $32.47 Million | +34.79% |
| 2017-12-31 | $24.09 Million | -- |
About Castle Biosciences Inc
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis fo… Read more